Praxis precision medicines to announce topline data from the phase 2 embold study of relutrigine (prax-562) in scn2a and scn8a developmental and epileptic encephalopathies on september 3, 2024

Boston, mass., sept. 02, 2024 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the phase 2 embold study of relutrigine (prax-562) in scn2a and scn8a developmental and epileptic encephalopathies (dees) on tuesday, september 3, 2024, prior to market open. following the announcement, the company will host a conference call and webcast presentation at 8:00 a.m. et to discuss the trial results.
PRAX Ratings Summary
PRAX Quant Ranking